Design Therapeutics Overview
- Status
-
Public
- Employees
-
60
- Stock Symbol
-
DSGN
- Share Price
-
$9.02
- (As of Friday Closing)
Design Therapeutics General Information
Description
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
Contact Information
Website
www.designtx.comCorporate Office
- 6005 Hidden Valley Road
- Suite 110
- Carlsbad, CA 92011
- United States
Corporate Office
- 6005 Hidden Valley Road
- Suite 110
- Carlsbad, CA 92011
- United States
Design Therapeutics Stock Performance
As of 20-Nov-2026, Design Therapeutics’s stock price is $9.02. Its current market cap is $578M with 64M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $9.02 | $9.32 | $7.82 - $17.25 | $578M | 64M | 555K | -$1.20 |
Design Therapeutics Financials Summary
As of 30-Sep-2026, Design Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 581,917 | 330,093 | 97,800 | (139,316) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (81,682) | (78,845) | (61,787) | (77,653) |
| Net Income | (74,086) | (69,792) | (49,588) | (66,862) |
| Total Assets | 216,808 | 226,203 | 252,093 | 289,643 |
| Total Debt | 2,514 | 1,535 | 2,334 | 3,050 |
Design Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Design Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Design Therapeutics Comparisons
Industry
Financing
Details
Design Therapeutics Competitors (43)
One of Design Therapeutics’s 43 competitors is NGM Biopharmaceuticals, a Private Equity-Backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NGM Biopharmaceuticals | Private Equity-Backed | South San Francisco, CA | ||||
| Beam Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland | ||||
| Lisata Therapeutics | Corporation | Basking Ridge, NJ | ||||
| Capricor Therapeutics | Formerly VC-backed | San Diego, CA |
Design Therapeutics Patents
Design Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026213229-A1 | Methods and compounds for treating genetic disease | Pending | 01-Apr-2025 | ||
| WO-2026107489-A1 | Soluble formulations | Pending | 18-Nov-2024 | ||
| WO-2026107406-A1 | P53 heterobifunctional conjugates and uses thereof | Pending | 15-Nov-2024 | ||
| WO-2026015815-A1 | Methods of treating haploinsufficiency disorders | Pending | 12-Jul-2024 | ||
| AU-2024394822-A1 | Compounds and methods for treating sickle cell disease | Pending | 08-Dec-2023 | C07D401/14 |
Design Therapeutics Signals
Design Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Design Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
39.27 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Design Therapeutics FAQs
-
Where is Design Therapeutics headquartered?
Design Therapeutics is headquartered in Carlsbad, CA.
-
What is the size of Design Therapeutics?
Design Therapeutics has 60 total employees.
-
What industry is Design Therapeutics in?
Design Therapeutics’s primary industry is Drug Discovery.
-
Is Design Therapeutics a private or public company?
Design Therapeutics is a Public company.
-
What is Design Therapeutics’s stock symbol?
The ticker symbol for Design Therapeutics is DSGN.
-
What is the current stock price of Design Therapeutics?
As of 20-Nov-2026 the stock price of Design Therapeutics is $9.02.
-
What is the current market cap of Design Therapeutics?
The current market capitalization of Design Therapeutics is $578M.
-
Who are Design Therapeutics’s competitors?
NGM Biopharmaceuticals, Beam Therapeutics, CRISPR Therapeutics, Lisata Therapeutics, and Capricor Therapeutics are some of the 43 competitors of Design Therapeutics.
-
What is Design Therapeutics’s annual earnings per share (EPS)?
Design Therapeutics’s EPS for 12 months was -$1.20.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process